• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Incyte Corp.

    6/18/25 4:01:35 PM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $INCY alert in real time by email
    S-8 1 tm2517983d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on June 18, 2025.

    Registration No. 333-

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form S-8

     

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    INCYTE CORPORATION

    (Exact name of registrant as specified in its charter)

     

    Delaware   94-3136539
    (State or other jurisdiction of   (I.R.S. Employer
    incorporation or organization)   Identification No.)
         
    1801 Augustine Cut-Off
    Wilmington, Delaware
      19803
    (Address of Principal Executive Offices)   (Zip Code)
         
    INCYTE CORPORATION AMENDED AND RESTATED
    2010 STOCK INCENTIVE PLAN
    (Full title of the plan)
         
    HERVÉ HOPPENOT   Copy to:
    President and Chief Executive Officer   STANTON D. WONG
    Incyte Corporation   Pillsbury Winthrop Shaw Pittman LLP
    1801 Augustine Cut-Off
    Wilmington, Delaware

    (302) 498-6700
      Four Embarcadero Center, 22nd Floor
    San Francisco, California 94111
    (415) 983-1000
    (Name, address and telephone number
    , including area code, of agent for service)
       

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer ” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

      

    Large accelerated filer x   Accelerated filer ¨
         
    Non-accelerated filer ¨
    (Do not check if a smaller reporting company)
      Smaller reporting company ¨
        Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

     

    PART I

     

    INFORMATION REQUIRED PURSUANT

    TO GENERAL INSTRUCTION E TO FORM S-8

     

    General Instruction E Information

     

    This registration statement (the “Registration Statement”) is being filed for the purpose of increasing the number of securities of the same class as other securities for which a Registration Statement of Incyte Corporation (the “Registrant”) on Form S-8 relating to the same employee benefit plan is effective.

     

    The Registrant’s Form S-8 Registration Statements filed with the Securities and Exchange Commission on June 15, 2010 (File No. 333-167526), June 15, 2011 (File No. 333-174918), June 19, 2012 (File No. 333-182218), June 18, 2013 (File No. 333-189424), August 6, 2014 (File No. 333-197907), June 17, 2016 (File No. 333-212104), May 24, 2018 (File No. 333-225181), April 30, 2019 (File No. 333-231129), June 11, 2021 (File No. 333-257041), and June 30, 2023 (File No. 333-273057) are hereby incorporated by reference.

     

    Part II

     

    Information Required in the Registration Statement

     

    Item 3.Incorporation of Documents by Reference.

     

    The following documents previously filed by Registrant with the Securities and Exchange Commission are hereby incorporated by reference in this Registration Statement:

     

    (1)Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024;

     

    (2)Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025;

     

    (3)Registrant’s Current Reports on Form 8-K filed on January 10, 2025, May 14, 2025, and June 11, 2025; and

     

    (4)The description of the Common Stock contained in Registrant’s Registration Statement on Form 8-A filed January 5, 1996.

     

    In addition, all documents subsequently filed by Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents. The Registrant is not, however, incorporating, in each case, any documents or information that the Registrant is deemed to furnish and not file in accordance with Securities and Exchange Commission rules.

     

    Any statement contained in this Registration Statement or in a document incorporated by reference in this Registration Statement shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in this Registration Statement or in any subsequently filed document that is deemed to be incorporated by reference in this Registration Statement modifies or supersedes such statement.

     

    Item 8.Exhibits

     

    Exhibit  
    Number Exhibit
       
    5.1 Opinion of Pillsbury Winthrop Shaw Pittman LLP.
    23.1 Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm.
    23.2 Consent of Pillsbury Winthrop Shaw Pittman LLP (included in Exhibit 5.1).
    24.1 Power of Attorney (included on the signature page hereto).
    107.1 Calculation of Filing Fee Tables

     

    1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8, and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Wilmington, State of Delaware, on June 18, 2025.

     

      INCYTE CORPORATION
       
       
      By /s/ Hervé Hoppenot
        Hervé Hoppenot
        President and Chief Executive Officer (Principal Executive Officer)

     

    POWER OF ATTORNEY

     

    KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Hervé Hoppenot, Christiana Stamoulis, and Sheila Denton, and each of them, his or her true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments, including post-effective amendments, to this Registration Statement, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or her substitute or substitutes, may do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the date indicated:

     

    Signature   Title   Date
    /s/ Hervé Hoppenot   President and Chief Executive Officer  
    Hervé Hoppenot   (Principal Executive Officer) and Chairman   June 18, 2025
             
    /s/ Christiana Stamoulis   Executive Vice President and Chief Financial Officer  
    Christiana Stamoulis   (Principal Financial Officer)   June 18, 2025
             
    /s/ Thomas R. Tray   Vice President and Chief Accounting Officer  
    Thomas R. Tray   (Principal Accounting Officer)   June 18, 2025
             
    /s/ Julian C. Baker   Director  
    Julian C. Baker       June 18, 2025
             
    /s/ Jean-Jacques Bienaimé   Director  
    Jean-Jacques Bienaimé       June 18, 2025
             
    /s/ Otis W. Brawley   Director  
    Otis W. Brawley       June 18, 2025
             
    /s/ Paul J. Clancy   Director  
    Paul J. Clancy       June 18, 2025
             
    /s/ Jacqualyn A. Fouse   Director  
    Jacqualyn A. Fouse       June 18, 2025
             
    /s/ Edmund P. Harrigan   Director  
    Edmund P. Harrigan       June 18, 2025
             
    /s/ Katherine A. High   Director  
    Katherine A. High       June 18, 2025
             
    /s/ Susanne Schaffert   Director  
    Susanne Schaffert       June 18, 2025

     

    2

    Get the next $INCY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INCY

    DatePrice TargetRatingAnalyst
    12/8/2025$121.00Neutral → Outperform
    Mizuho
    11/3/2025$125.00Neutral → Buy
    Guggenheim
    10/8/2025Outperform → Perform
    Oppenheimer
    8/6/2025$89.00Equal Weight → Overweight
    Wells Fargo
    8/1/2025$90.00Overweight
    Barclays
    6/16/2025$107.00Hold → Buy
    Stifel
    3/18/2025Buy → Neutral
    Guggenheim
    3/18/2025Outperform → Mkt Perform
    William Blair
    More analyst ratings

    $INCY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & Chief Scientific Officer Mayes Patrick A sold $554,965 worth of shares (5,808 units at $95.55), decreasing direct ownership by 9% to 60,011 units (SEC Form 4)

    4 - INCYTE CORP (0000879169) (Issuer)

    12/12/25 4:01:54 PM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Director Hoppenot Herve covered exercise/tax liability with 2,843 shares, decreasing direct ownership by 0.86% to 326,803 units (SEC Form 4)

    4 - INCYTE CORP (0000879169) (Issuer)

    12/10/25 4:06:42 PM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    EVP & Chief Medical Officer Stein Steven H covered exercise/tax liability with 17,093 shares and sold $2,324,438 worth of shares (22,664 units at $102.56), decreasing direct ownership by 39% to 63,129 units (SEC Form 4)

    4 - INCYTE CORP (0000879169) (Issuer)

    12/3/25 4:36:44 PM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $INCY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for JAKAFI issued to INCYTE CORP

    Submission status for INCYTE CORP's drug JAKAFI (SUPPL-25) with active ingredient RUXOLITINIB PHOSPHATE has changed to 'Approval' on 09/27/2021. Application Category: NDA, Application Number: 202192, Application Classification: Labeling

    9/28/21 5:20:01 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    FDA Approval for JAKAFI issued to INCYTE CORP

    Submission status for INCYTE CORP's drug JAKAFI (SUPPL-23) with active ingredient RUXOLITINIB PHOSPHATE has changed to 'Approval' on 09/22/2021. Application Category: NDA, Application Number: 202192, Application Classification: Efficacy

    9/23/21 5:11:12 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    FDA Approval for OPZELURA issued to INCYTE CORP

    Submission status for INCYTE CORP's drug OPZELURA (ORIG-1) with active ingredient RUXOLITINIB has changed to 'Approval' on 09/21/2021. Application Category: NDA, Application Number: 215309, Application Classification: Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated

    9/22/21 11:16:23 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $INCY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $INCY
    SEC Filings

    View All

    $INCY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Incyte upgraded by Mizuho with a new price target

    Mizuho upgraded Incyte from Neutral to Outperform and set a new price target of $121.00

    12/8/25 8:14:28 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Incyte upgraded by Guggenheim with a new price target

    Guggenheim upgraded Incyte from Neutral to Buy and set a new price target of $125.00

    11/3/25 9:08:28 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Incyte downgraded by Oppenheimer

    Oppenheimer downgraded Incyte from Outperform to Perform

    10/8/25 8:24:02 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Incyte Corp. filed SEC Form 8-K: Leadership Update

    8-K - INCYTE CORP (0000879169) (Filer)

    12/12/25 11:34:47 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 144 filed by Incyte Corp.

    144 - INCYTE CORP (0000879169) (Subject)

    11/21/25 4:17:23 PM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SCHEDULE 13G filed by Incyte Corp.

    SCHEDULE 13G - INCYTE CORP (0000879169) (Subject)

    11/10/25 8:35:23 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Incyte Announces Change to its Board of Directors

    Incyte (NASDAQ:INCY) today announced the resignation of Hervé Hoppenot from the Company's Board of Directors, effective immediately. As previously announced, Mr. Hoppenot had been serving as an advisor to the Chief Executive Officer (CEO) and as a member of the Board during a planned transition period. Mr. Hoppenot joined Incyte in 2014 and previously served as Chairman and CEO. "On behalf of the Board of Directors, I would like to thank Hervé for his steadfast leadership, vision and guidance throughout his tenure, which helped grow Incyte into a leading, innovative company," said Julian Baker, Managing Partner of Baker Bros. Advisors LP and Incyte's Chairman of the Board. "Hervé leaves a

    12/12/25 8:30:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Incyte's First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA

    The Company plans to initiate a Phase 3 program evaluating INCA033989 in essential thrombocythemia (ET) patients with all types of CALR mutations in mid-2026, following alignment with regulators Updated safety and efficacy data for INCA033989 in ET, and new data in myelofibrosis (MF), will be presented at the upcoming 2025 ASH Annual Meeting Incyte (NASDAQ:INCY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, for the treatment of patients with essential thrombocythemia (ET) harboring a Type 1 CALR mutation who are resistant or intoler

    12/7/25 9:30:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025

    Rapid and robust reductions in spleen volume and symptoms, and improvements in anemia were observed with INCA033989 as monotherapy and in combination with ruxolitinib (Jakafi®) in patients with myelofibrosis (MF) harboring a CALR mutation (mutCALR) Results demonstrate a favorable safety profile for INCA033989 as a monotherapy and in combination with ruxolitinib – no dose limiting toxicities were reported and a maximum tolerated dose was not reached A reduction in peripheral blood mutCALR variant allele frequency (VAF) from baseline was observed in MF patients in the INCA033989 monotherapy arm with ≥1 post-baseline VAF measurement Exploratory analyses from the clinical studies of INCA

    12/7/25 9:30:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $INCY
    Leadership Updates

    Live Leadership Updates

    View All

    Incyte Appoints Richard Hoffman as Executive Vice President and General Counsel

    Incyte (NASDAQ:INCY) announces the appointment of Richard Hoffman as Executive Vice President and General Counsel effective today, December 1, 2025. In his new role, Mr. Hoffman will serve as a key member of the Executive Leadership Team and be responsible for the Company's legal and compliance teams. "Richard joins us with a distinguished background, including many years of experience as a partner at a premier law firm, and a proven track record advising biopharma companies on corporate governance, strategic transactions, intellectual property and litigation," said Bill Meury, President and Chief Executive Officer, Incyte. "He possesses exceptional legal acumen and sound judgment to help

    12/1/25 8:00:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer

    Incyte (NASDAQ:INCY) announces that Dave Gardner has been appointed Executive Vice President and Chief Strategy Officer (CSO) effective today, September 22, 2025. In his new role, Mr. Gardner will serve as a key member of the Executive Leadership Team and be responsible for the Company's strategy and business development. "Dave possesses a unique combination of business acumen, scientific knowledge and deep industry experience. His extensive background in biopharma investing will bring a fresh perspective and a focused, judicious approach to corporate development," said Bill Meury, President and Chief Executive Officer, Incyte. "Dave will play a pivotal role in developing a coherent and e

    9/22/25 7:30:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Incyte Announces the Appointment of Soni Basi as Executive Vice President and Chief Human Resources Officer

    Incyte (NASDAQ:INCY) announces that Soni Basi has been appointed Executive Vice President and Chief Human Resources Officer (CHRO) effective today, August 25, 2025. In her new role, Ms. Basi will serve as a key member of the Executive Leadership Team and be responsible for shaping the Company's global human resources strategy including talent acquisition, organizational design and professional development. "Soni has extensive knowledge and experience in all aspects of human resources," said Bill Meury, President and Chief Executive Officer, Incyte. "She is a skilled professional and collaborative leader who will bring a strategic mindset and operational focus to the company. Soni will pla

    8/25/25 8:00:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $INCY
    Financials

    Live finance-specific insights

    View All

    Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025

    Rapid and robust reductions in spleen volume and symptoms, and improvements in anemia were observed with INCA033989 as monotherapy and in combination with ruxolitinib (Jakafi®) in patients with myelofibrosis (MF) harboring a CALR mutation (mutCALR) Results demonstrate a favorable safety profile for INCA033989 as a monotherapy and in combination with ruxolitinib – no dose limiting toxicities were reported and a maximum tolerated dose was not reached A reduction in peripheral blood mutCALR variant allele frequency (VAF) from baseline was observed in MF patients in the INCA033989 monotherapy arm with ≥1 post-baseline VAF measurement Exploratory analyses from the clinical studies of INCA

    12/7/25 9:30:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Incyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting

    INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, will be showcased in three presentations, including new Phase 1 monotherapy and combination data in myelofibrosis (MF), updated data in essential thrombocythemia (ET) and translational data demonstrating disease modifying activity in both ET and MF. Additionally, the more than 50 abstracts accepted at ASH include new and updated data from Incyte's MPN, GVHD and hematology programs including interim safety data evaluating axatilimab (Niktimvo™) in combination with ruxolitinib in GVHD Incyte to host an investor event and webcast highlighting the mutCALR data from the oral presentation at ASH on

    11/3/25 9:31:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates

    Total revenues of $1.37 billion in the third quarter of 2025, reflecting 20% growth compared to the third quarter of 2024 Jakafi® (ruxolitinib) net product revenue of $791 million, an increase of 7% compared to the same period in 2024 Opzelura® (ruxolitinib) cream net product revenue of $188 million, an increase of 35% compared to the prior year period Hematology-Oncology portfolio net product revenues of $171 million, including Niktimvo™ (axatilimab-csfr) net revenue of $46 million Raises 2025 full year net product revenue guidance to $4.23 - $4.32 billion Conference Call and Webcast Scheduled Today at 8:00 a.m. ET Incyte (NASDAQ:INCY) today reported financial results for the t

    10/28/25 7:00:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $INCY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Incyte Corp.

    SC 13G - INCYTE CORP (0000879169) (Subject)

    10/17/24 9:39:00 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Amendment: SEC Form SC 13D/A filed by Incyte Corp.

    SC 13D/A - INCYTE CORP (0000879169) (Subject)

    6/14/24 6:23:05 PM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13D/A filed by Incyte Corp. (Amendment)

    SC 13D/A - INCYTE CORP (0000879169) (Subject)

    5/13/24 6:06:33 PM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care